Search

Your search keyword '"Vogt, Bruno"' showing total 733 results
Start Over Author "Vogt, Bruno"
733 results on '"Vogt, Bruno"'

1. Self-reported caffeine consumption miss-matched consumption measured by plasma levels of caffeine and its metabolites: results from two population-based studies

Author

Laaboub, Nermine, Ranjbar, Setareh, Strippoli, Marie-Pierre F., Marques-Vidal, Pedro, Estoppey-Younes, Sandrine, Ponte, Belen, Pruijm, Menno, Vogt, Bruno, Ansermot, Nicolas, Crettol, Séverine, Vandenberghe, Frederik, Vollenweider, Peter, Preisig, Martin, Bochud, Murielle, and EAP, Chin B.

Published
2024
Full Text
View/download PDF

2. Genome-wide association analyses define pathogenic signaling pathways and prioritize drug targets for IgA nephropathy

Author

Kiryluk, Krzysztof, Sanchez-Rodriguez, Elena, Zhou, Xu-Jie, Zanoni, Francesca, Liu, Lili, Mladkova, Nikol, Khan, Atlas, Marasa, Maddalena, Zhang, Jun Y., Balderes, Olivia, Sanna-Cherchi, Simone, Bomback, Andrew S., Canetta, Pietro A., Appel, Gerald B., Radhakrishnan, Jai, Trimarchi, Hernan, Sprangers, Ben, Cattran, Daniel C., Reich, Heather, Pei, York, Ravani, Pietro, Galesic, Kresimir, Maixnerova, Dita, Tesar, Vladimir, Stengel, Benedicte, Metzger, Marie, Canaud, Guillaume, Maillard, Nicolas, Berthoux, Francois, Berthelot, Laureline, Pillebout, Evangeline, Monteiro, Renato, Nelson, Raoul, Wyatt, Robert J., Smoyer, William, Mahan, John, Samhar, Al-Akash, Hidalgo, Guillermo, Quiroga, Alejandro, Weng, Patricia, Sreedharan, Raji, Selewski, David, Davis, Keefe, Kallash, Mahmoud, Vasylyeva, Tetyana L., Rheault, Michelle, Chishti, Aftab, Ranch, Daniel, Wenderfer, Scott E., Samsonov, Dmitry, Claes, Donna J., Akchurin, Oleh, Goumenos, Dimitrios, Stangou, Maria, Nagy, Judit, Kovacs, Tibor, Fiaccadori, Enrico, Amoroso, Antonio, Barlassina, Cristina, Cusi, Daniele, Del Vecchio, Lucia, Battaglia, Giovanni Giorgio, Bodria, Monica, Boer, Emanuela, Bono, Luisa, Boscutti, Giuliano, Caridi, Gianluca, Lugani, Francesca, Ghiggeri, GianMarco, Coppo, Rosanna, Peruzzi, Licia, Esposito, Vittoria, Esposito, Ciro, Feriozzi, Sandro, Polci, Rosaria, Frasca, Giovanni, Galliani, Marco, Garozzo, Maurizio, Mitrotti, Adele, Gesualdo, Loreto, Granata, Simona, Zaza, Gianluigi, Londrino, Francesco, Magistroni, Riccardo, Pisani, Isabella, Magnano, Andrea, Marcantoni, Carmelita, Messa, Piergiorgio, Mignani, Renzo, Pani, Antonello, Ponticelli, Claudio, Roccatello, Dario, Salvadori, Maurizio, Salvi, Erica, Santoro, Domenico, Gembillo, Guido, Savoldi, Silvana, Spotti, Donatella, Zamboli, Pasquale, Izzi, Claudia, Alberici, Federico, Delbarba, Elisa, Florczak, Michał, Krata, Natalia, Mucha, Krzysztof, Pączek, Leszek, Niemczyk, Stanisław, Moszczuk, Barbara, Pańczyk-Tomaszewska, Malgorzata, Mizerska-Wasiak, Malgorzata, Perkowska-Ptasińska, Agnieszka, Bączkowska, Teresa, Durlik, Magdalena, Pawlaczyk, Krzysztof, Sikora, Przemyslaw, Zaniew, Marcin, Kaminska, Dorota, Krajewska, Magdalena, Kuzmiuk-Glembin, Izabella, Heleniak, Zbigniew, Bullo-Piontecka, Barbara, Liberek, Tomasz, Dębska-Slizien, Alicja, Hryszko, Tomasz, Materna-Kiryluk, Anna, Miklaszewska, Monika, Szczepańska, Maria, Dyga, Katarzyna, Machura, Edyta, Siniewicz-Luzeńczyk, Katarzyna, Pawlak-Bratkowska, Monika, Tkaczyk, Marcin, Runowski, Dariusz, Kwella, Norbert, Drożdż, Dorota, Habura, Ireneusz, Kronenberg, Florian, Prikhodina, Larisa, van Heel, David, Fontaine, Bertrand, Cotsapas, Chris, Wijmenga, Cisca, Franke, Andre, Annese, Vito, Gregersen, Peter K., Parameswaran, Sreeja, Weirauch, Matthew, Kottyan, Leah, Harley, John B., Suzuki, Hitoshi, Narita, Ichiei, Goto, Shin, Lee, Hajeong, Kim, Dong Ki, Kim, Yon Su, Park, Jin-Ho, Cho, BeLong, Choi, Murim, Van Wijk, Ans, Huerta, Ana, Ars, Elisabet, Ballarin, Jose, Lundberg, Sigrid, Vogt, Bruno, Mani, Laila-Yasmin, Caliskan, Yasar, Barratt, Jonathan, Abeygunaratne, Thilini, Kalra, Philip A., Gale, Daniel P., Panzer, Ulf, Rauen, Thomas, Floege, Jürgen, Schlosser, Pascal, Ekici, Arif B., Eckardt, Kai-Uwe, Chen, Nan, Xie, Jingyuan, Lifton, Richard P., Loos, Ruth J. F., Kenny, Eimear E., Ionita-Laza, Iuliana, Köttgen, Anna, Julian, Bruce A., Novak, Jan, Scolari, Francesco, Zhang, Hong, and Gharavi, Ali G.

Published
2023
Full Text
View/download PDF

6. The impact of treatment with avacopan on health-related quality of life in antineutrophil cytoplasmic antibody-associated vasculitis: a post-hoc analysis of data from the ADVOCATE trial

Author

Au Peh, Chen, Chakera, Aron, Cooper, Bruce, Kurtkoti, Jagadeesh, Langguth, Daman, Levidiotis, Vicki, Luxton, Grant, Mount, Peter, Mudge, David, Noble, Euan, Phoon, Richard, Ranganathan, Dwarakanathan, Ritchie, Angus, Ryan, Jessica, Suranyi, Michael, Rosenkranz, Alexander, Lhotta, Karl, Kronbichler, Andreas, Demoulin, Nathalie, Bovy, Christophe, Hellemans, Rachel, Hougardy, Jean-Michel, Sprangers, Ben, Wissing, Karl Martin, Pagnoux, Christian, Barbour, Sean, Brachemi, Soumeya, Cournoyer, Serge, Girard, Louis-Philippe, Laurin, Louis-Philippe, Liang, Patrick, Philibert, David, Walsh, Michael, Tesar, Vladimir, Becvar, Radim, Horak, Pavel, Rychlik, Ivan, Szpirt, Wladimir, Dieperink, Hans, Gregersen, Jon Waarst, Ivarsen, Per, Krarup, Elizabeth, Lyngsoe, Cecilie, Rigothier, Claire, Augusto, Jean-Francois, Belot, Alexandre, Chauveau, Dominique, Cornec, Divi, Jourde-Chiche, Noemie, Ficheux, Maxence, Karras, Alexandre, Klein, Alexandre, Maurier, Francois, Mesbah, Rafik, Moranne, Olivier, Neel, Antoine, Quemeneur, Thomas, Saadoun, David, Terrier, Benjamin, Zaoui, Philippe, Schaier, Matthias, Benck, Urs Tobias, Bergner, Raoul, Busch, Martin, Floege, Juergen, Grundmann, Franziska, Haller, Hermann, Haubitz, Marion, Hellmich, Bernhard, Henes, Joerg Christoph, Hohenstein, Bernd, Hugo, Christian, Iking-Konert, Christof, Arndt, Fabian, Kubacki, T, Kotter, Ina, Lamprecht, Peter, Lindner, Tom, Halbritter, Jan, Mehling, Heidrun, Schönermarck, Ulf, Venhoff, Nils, Vielhauer, Volker, Witzke, Oliver, Szombati, Istvan, Szucs, Gabriella, Garibotto, Giacomo, Alberici, Federico, Brunetta, Enrico, Dagna, Lorenzo, De Vita, Salvatore, Emmi, Giacomo, Gabrielli, Armando, Manenti, Lucio, Pieruzzi, Federico, Roccatello, Dario, Salvarani, Carlo, Harigai, Masayoshi, Dobashi, Hiroaki, Atsumi, Tatsuya, Fujimoto, Shoichi, Hagino, Noboru, Ihata, Atsushi, Kaname, Shinya, Kaneko, Yuko, Katagiri, Akira, Katayama, Masao, Kirino, Yohei, Kitagawa, Kiyoki, Komatsuda, Atsushi, Kono, Hajime, Kurasawa, Takahiko, Matsumura, Ryutaro, Mimura, Toshihide, Morinobu, Akio, Murakawa, Yohko, Naniwa, Taio, Nanki, Toshihiro, Ogawa, Noriyoshi, Oshima, Hisaji, Sada, Kenei, Sugiyama, Eiji, Takeuchi, Tohru, Taki, Hirofumi, Tamura, Naoto, Tsukamoto, Tatsuo, Yamagata, Kunihiro, Yamamura, Masahiro, van Daele, Paulus Leon Arthur, Rutgers, Abraham, Teng, Y.K. Onno, Walker, Robert, Chua, Ignatius, Collins, Michael, Rabindranath, Kannaiyan, de Zoysa, Janak, Svensson, My Hanna Sofia, Grevbo, Bard-Waldum, Kalstad, Synove, Little, Mark, Clarkson, Michael, Molloy, Eamonn, Agraz Pamplona, Irene, Anton, Jordi, Barrio Lucia, Vicente, Ciggaran, Secundino, Cinta Cid, Maria, Diaz Encarnacion, Montserrat, Fulladosa Oliveras, Xavier, Jose Soler, Maria, Marco Rusinol, Helena, Praga, Manuel, Quintana Porras, Luis, Segarra, Alfons, Bruchfeld, Annette, Segelmark, Marten, Soveri, Inga, Thomaidi, Eleni, Westman, Kerstin, Neumann, Thomas, Burnier, Michel, Daikeler, Thomas, Dudler, Jean, Hauser, Thomas, Seeger, Harald, Vogt, Bruno, Burton, James, Al Jayyousi, Reem, Amin, Tania, Andrews, Jacqueline, Baines, Laura Anne, Brogan, Paul, Dasgupta, Bhaskar, Doulton, Timothy William Ronald, Flossmann, Oliver, Griffin, Sian V., Harper, Janice Marian, Harper, Lorraine, Kidder, Dana, Klocke, Rainer, Lanyon, Peter Charles, Luqmani, Raashid, McLaren, John Stuart, Makanjuola, David Osagie, McCann, Liza, Nandagudi, Anupama C., Selvan, Shilpa, O'Riordan, Edmond, Patel, Mumtaz, Patel, Rajan Kantilal, Pusey, Charles Dickson, Rajakariar, Ravindra, Robson, Joanna C., Robson, Michael, Salama, Alan David, Smyth, Lucy, Sznajd, Jan, Taylor, Joanne, Sreih, Antonie G., Belilos, Elise, Bomback, Andrew S., Carlin, Jeffrey, Chang Chen Lin, Yih, Derebail, Vimal K., Dragoi, Serban, Dua, Anisha, Forbess, Lindsy, Geetha, Duvuru, Gipson, Patrick, Gohh, Reginald, Greenwood, Gregory Todd, Hugenberg, Steven T., Jimenez, Richard A.H., Kaskas, Marwan Omar, Kermani, Tanaz, Kivitz, Alan J., Koening, Curry, Langford, Carol A., Marder, Galina, Mohamed, Amr Ahmed El-Huesseini, Monach, Paul, Neyra, Nilda Roxana, Niemer, Gregory W., Niles, John, Obi, Reginald, Owens, Charles, Parks, Deborah L., Podoll, Amber S., Rovin, Brad, Sam, R, Shergy, William Julius, Silva, Arnold Lawrence, Specks, Ulrich, Spiera, Robert, Springer, Jason M., Striebich, Christopher Charles, Swarup, Areena, Thakar, Surabhi, Tiliakos, Athan N., Tsai, Yong, Waguespack, Dia R., Chester Wasko, Mary, Strand, Vibeke, Jayne, David R W, Horomanski, Audra, Yue, Huibin, Bekker, Pirow, and Merkel, Peter A

Published
2023
Full Text
View/download PDF

12. COMPARISON OF OFFICE-BASED BLOOD PRESSURE TO DAYTIME CUFFLESS BLOOD PRESSURE IN A POPULATION-BASED STUDY

Author

Zahnd, Joachim, primary, Chelbi, Sonia T., additional, Gagliano, Jvan Gianini Vanessa, additional, Marot, Peggy, additional, Ackermann, Daniel, additional, Durer, Isabelle, additional, Beuschlein, Felix, additional, Suter, Paolo, additional, Vogt, Bruno, additional, Gabutti, Luca, additional, Bochud, Murielle, additional, and Wuerzner, Gregoire, additional

Published
2024
Full Text
View/download PDF

13. Urinary Biomarkers for Cell Cycle Arrest TIMP-2 and IGFBP7 for Prediction of Graft Function Recovery after Kidney Transplantation

Author

Gäckler, Anja, primary, Ertasoglu, Onurcan, additional, Rohn, Hana, additional, Friebus-Kardash, Justa, additional, Ickerott, Philipp-Christopher, additional, Witzke, Oliver, additional, Kribben, Andreas, additional, Vogt, Bruno, additional, Dahdal, Suzan, additional, Arampatzis, Spyridon, additional, and Eisenberger, Ute, additional

Published
2024
Full Text
View/download PDF

16. Prevalence and characteristics of genetic disease in adult kidney stone formers.

Author

Anderegg, Manuel A, Olinger, Eric G, Bargagli, Matteo, Geraghty, Rob, Taylor, Lea, Nater, Alexander, Bruggmann, Rémy, Sayer, John A, Vogt, Bruno, Schaller, André, and Fuster, Daniel G

Subjects
KIDNEY stones, MEDICAL genetics, GENETIC disorders, MEDICAL genomics, CALCIUM oxalate
Abstract

Background Molecular mechanisms of kidney stone formation remain unknown in most patients. Previous studies have shown a high heritability of nephrolithiasis, but data on the prevalence and characteristics of genetic disease in unselected adults with nephrolithiasis are lacking. This study was conducted to fill this important knowledge gap. Methods We performed whole exome sequencing in 787 participants in the Bern Kidney Stone Registry, an unselected cohort of adults with one or more past kidney stone episodes [kidney stone formers (KSFs)] and 114 non-kidney stone formers (NKSFs). An exome-based panel of 34 established nephrolithiasis genes was analysed and variants assessed according to American College of Medical Genetics and Genomics criteria. Pathogenic (P) or likely pathogenic (LP) variants were considered diagnostic. Results The mean age of KSFs was 47 ± 15 years and 18% were first-time KSFs. A Mendelian kidney stone disease was present in 2.9% (23/787) of KSFs. The most common genetic diagnoses were cystinuria (SLC3A1, SLC7A9; n  = 13), vitamin D-24 hydroxylase deficiency (CYP24A1; n  = 5) and primary hyperoxaluria (AGXT, GRHPR, HOGA1; n  = 3). Of the KSFs, 8.1% (64/787) were monoallelic for LP/P variants predisposing to nephrolithiasis, most frequently in SLC34A1/A3 or SLC9A3R1 (n  = 37), CLDN16 (n  = 8) and CYP24A1 (n  = 8). KSFs with Mendelian disease had a lower age at the first stone event (30 ± 14 versus 36 ± 14 years; P  = .003), were more likely to have cystine stones (23.4% versus 1.4%) and less likely to have calcium oxalate monohydrates stones (31.9% versus 52.5%) compared with KSFs without a genetic diagnosis. The phenotype of KSFs with variants predisposing to nephrolithiasis was subtle and showed significant overlap with KSFs without diagnostic variants. In NKSFs, no Mendelian disease was detected and LP/P variants were significantly less prevalent compared with KSFs (1.8% versus 8.1%). Conclusion Mendelian disease is uncommon in unselected adult KSFs, yet variants predisposing to nephrolithiasis are significantly enriched in adult KSFs. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

18. No extra-adrenal aldosterone production in various human cell lines

Author

Durrer, Isabelle, primary, Ackermann, Daniel, additional, Klossner, Rahel, additional, Grössl, Michael, additional, Vögel, Clarissa, additional, Du Toit, Therina, additional, Vogt, Bruno, additional, Jamin, Heidi, additional, Mohaupt, Markus G, additional, and Gennari-Moser, Carine, additional

Published
2024
Full Text
View/download PDF

19. Differential assessment of fluid compartments by bioimpedance in pediatric patients with kidney diseases

Author

Frey, Sandra M., Vogt, Bruno, Simonetti, Giacomo D., Büscher, Rainer, Habbig, Sandra, and Schaefer, Franz

Subjects
Children -- Diseases, Drinking (Physiology) -- Health aspects, Electrophysiology -- Measurement -- Health aspects -- Demographic aspects, Kidney diseases -- Diagnosis -- Care and treatment, Health
Abstract

Background The kidney is central for maintaining water balance. As a corollary, patients with impaired kidney function are prone to pathological fluid volumes. Total body water (TBW) is distributed between the extracellular (ECW) and intracellular fluid compartments (ICW). In clinical practice, the judgment of hydration status does not allow to distinguish between ECW and ICW. Here, we evaluate the hydration status in children with chronic kidney disease by analyzing TBW, ECW, and ICW. Methods Hydration was quantified using whole-body bioimpedance spectroscopy (BCM) in 128 outpatients (1-25 years, 52 girls). Forty-two were transplanted (TPL), 43 suffered from chronic kidney disease without kidney replacement therapy (CKD), 21 were on peritoneal dialysis (PD), and 22 on hemodialysis (HD). HD patients were investigated before, after, and sequentially during dialysis. Results The ECW and ICW values obtained by BCM were of the same magnitude as those from the literature using isotope dilution. When compared with a healthy control group, TBW was increased in 9 TPL, 9 CKD, 1 PD, and 11 HD patients before but in none after dialysis. The decline of overhydration during dialysis (p < 0.001, n = 22) correlated with the change in body weight (R.sup.2 = 0.62). The kinetics of fluid compartment changes assessed twice in six HD patients revealed a reproducible linear decay of the ECW/ICW ratio due to an increase of ICW and a decrease of ECW. Conclusion BCM quantifies TBW and acute changes of ECW and ICW in children with chronic kidney failure. The clinical utility of measuring TBW, ECW, and ICW should be defined in the future., Author(s): Sandra M. Frey [sup.1] [sup.2] , Bruno Vogt [sup.1] , Giacomo D. Simonetti [sup.3] , Rainer Büscher [sup.4] , Sandra Habbig [sup.5] , Franz Schaefer [sup.6] Author Affiliations: (1) [...]

Published
2021
Full Text
View/download PDF

21. Clinical and genetic spectra of autosomal dominant tubulointerstitial kidney disease due to mutations in UMOD and MUC1

Author

Olinger, Eric, Hofmann, Patrick, Kidd, Kendrah, Dufour, Inès, Belge, Hendrica, Schaeffer, Céline, Kipp, Anne, Bonny, Olivier, Deltas, Constantinos, Demoulin, Nathalie, Fehr, Thomas, Fuster, Daniel G., Gale, Daniel P., Goffin, Eric, Hodaňová, Kateřina, Huynh-Do, Uyen, Kistler, Andreas, Morelle, Johann, Papagregoriou, Gregory, Pirson, Yves, Sandford, Richard, Sayer, John A., Torra, Roser, Venzin, Christina, Venzin, Reto, Vogt, Bruno, Živná, Martina, Greka, Anna, Dahan, Karin, Rampoldi, Luca, Kmoch, Stanislav, Bleyer, Anthony J., Sr., and Devuyst, Olivier

Published
2020
Full Text
View/download PDF

25. Capacity for the management of kidney failure in the International Society of Nephrology Western Europe region: report from the 2023 ISN Global Kidney Health Atlas (ISN-GKHA)

Author

Pippias, Maria, Alfano, Gaetano, Kelly, Dearbhla M., Soler, Maria Jose, De Chiara, Letizia, Olanrewaju, Timothy O., Arruebo, Silvia, Bello, Aminu K., Caskey, Fergus J., Damster, Sandrine, Donner, Jo-Ann, Jha, Vivekanand, Johnson, David W., Levin, Adeera, Malik, Charu, Nangaku, Masaomi, Okpechi, Ikechi G., Tonelli, Marcello, Ye, Feng, Coppo, Rosanna, Lightstone, Liz, Amouzegar, Atefeh, Anders, Hans-Joachim, Baharani, Jyoti, Banerjee, Debasish, Bikbov, Boris, Brown, Edwina A., Cho, Yeoungjee, Claes, Kathleen, Clyne, Naomi, Davids, M. Razeen, Davison, Sara N., Diongole, Hassane M., Divyaveer, Smita, Dreyer, Gavin, Dudley, Jan, Ekrikpo, Udeme E., Ethier, Isabelle, Evans, Rhys D.R., Fan, Stanley L.S., Wing-Shing Fung, Winston, Gallieni, Maurizio, Ghimire, Anukul, Houston, Ghenette, Htay, Htay, Ibrahim, Kwaifa Salihu, Irish, Georgina, Jindal, Kailash, Khwaja, Arif, Lalji, Rowena, Liakopoulos, Vassilios, Luyckx, Valerie A., Macia, Manuel, Marti, Hans Peter, Messa, Piergiorgio, Müller, Thomas F., Nalado, Aisha M., Neuen, Brendon L., Nitsch, Dorothea, Nolasco, Fernando, Oberbauer, Rainer, Osman, Mohamed A., Papagianni, Aikaterini, Petrova, Anna, Piccoli, Giorgina Barbara, Plant, Liam, Remuzzi, Giuseppe, Riaz, Parnian, Roelofs, Joris J., Rudnicki, Michael, Saad, Syed, Sakajiki, Aminu Muhammad, Scheppach, Johannes B., See, Emily, Shroff, Rukshana, Solbu, Marit D., Sozio, Stephen M., Strippoli, Giovanni FM., Taal, Maarten W., Ashu, James Tataw, Tiv, Sophanny, Tungsanga, Somkanya, van der Net, Jeroen B., Vanholder, Raymond C., Viecelli, Andrea, Vinen, Katie, Vogt, Bruno, Wainstein, Marina, Weinstein, Talia, Wheeler, David C., Yeung, Emily K., and Zaidi, Deenaz

Abstract

Western Europe boasts advanced health care systems, robust kidney care guidelines, and a well-established health care workforce. Despite this, significant disparities in kidney replacement therapy incidence, prevalence, and transplant access exist. This paper presents the third International Society of Nephrology Global Kidney Health Atlas’s findings on kidney care availability, accessibility, affordability, and quality in 22 Western European countries, representing 99% of the region’s population. The known chronic kidney disease (CKD) prevalence across Western Europe averages 10.6%, slightly above the global median. Cardiovascular diseases account for a substantial portion of CKD-related deaths. Kidney failure incidence varies. Government health expenditure differs; however, most countries offer government-funded acute kidney injury, dialysis, and kidney transplantation care. Hemodialysis and peritoneal dialysis are universally available, with variations in the number of dialysis centers. Kidney transplantation is available in all countries (except for 3 microstates), with variable transplant center prevalence. Conservative kidney management (CKM) is increasingly accessible. The region’s kidney care workforce is substantial, exceeding global averages; however, workforce shortages are reported. Barriers to optimal kidney care include limited workforce capacity, lack of surveillance mechanisms, and suboptimal integration into national noncommunicable disease (NCD) strategies. Policy recognition of CKD as a health priority varies across countries. Although Western Europe exhibits strong kidney care infrastructure, opportunities for improvement exist, particularly in CKD prevention, surveillance, awareness, and policy implementation. Efforts to improve CKD care should include automated detection, educational support, and enhanced workflows. Based on these findings, health care professionals, stakeholders, and policymakers are called to act to enhance kidney care across the region.

Published
2024
Full Text
View/download PDF

26. The urine-to-plasma urea concentration ratio is associated with eGFR and eGFR decline over time in a population cohort.

Author

Petrovic, Dusan, Bankir, Lise, Ponte, Belén, Pruijm, Menno, Corre, Tanguy, Ghobril, Jean-Pierre, Bouatou, Yassine, Ackermann, Daniel, Vogt, Bruno, and Bochud, Murielle

Subjects
EPIDERMAL growth factor receptors, UREA, KIDNEY physiology, GLOMERULAR filtration rate, URIC acid
Abstract

Background Evaluation of renal function and of factors associated with its decline are important public health issues. Besides markers of glomerular function [e.g. glomerular filtration rate (GFR)], those of tubular functions are rarely evaluated. Urea, the most abundant urinary solute, is markedly concentrated in urine when compared with plasma. We explored the urine-to-plasma ratio of urea concentrations (U/P urea ratio) as a marker of tubular functions. Methods We evaluated the relationship of the U/P urea ratio with eGFR at baseline in 1043 participants (48 ± 17 years) from the Swiss Kidney Project on Genes in Hypertension (SKIPOGH) population-based cohort, using mixed regression. In 898 participants, we assessed the relation between U/P urea ratio and renal function decline between two study waves 3 years apart. We studied U/P ratios for osmolarity, Na, K and uric acid for comparison. Results In a transversal study at baseline, estimated GFR (eGFR) was positively associated with U/P-urea ratio [βscaled = 0.08, 95% CI (0.04; 0.13)] but not with the U/P ratio of osmolarity. Considering separately participants with renal function >90 or ≤90 mL/min × 1.73 m2, this association was observed only in those with reduced renal function. In the longitudinal study, eGFR declined at a mean rate of 1.2 mL/min per year. A significant association was observed between baseline U/P urea ratio and eGFR decline [βscaled = 0.08, 95% CI (0.01; 0.15)]. A lower baseline U/P urea ratio was associated with a greater eGFR decline. Conclusion This study provides evidence that the U/P urea ratio is an early marker of kidney function decline in the general adult population. Urea is easy to measure with well-standardized techniques and at low cost. Thus, the U/P urea ratio could become an easily available tubular marker for evaluating renal function decline. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

27. The impact of treatment with avacopan on health-related quality of life in antineutrophil cytoplasmic antibody-associated vasculitis: a post-hoc analysis of data from the ADVOCATE trial

Author

Strand, Vibeke, primary, Jayne, David R W, additional, Horomanski, Audra, additional, Yue, Huibin, additional, Bekker, Pirow, additional, Merkel, Peter A, additional, Au Peh, Chen, additional, Chakera, Aron, additional, Cooper, Bruce, additional, Kurtkoti, Jagadeesh, additional, Langguth, Daman, additional, Levidiotis, Vicki, additional, Luxton, Grant, additional, Mount, Peter, additional, Mudge, David, additional, Noble, Euan, additional, Phoon, Richard, additional, Ranganathan, Dwarakanathan, additional, Ritchie, Angus, additional, Ryan, Jessica, additional, Suranyi, Michael, additional, Rosenkranz, Alexander, additional, Lhotta, Karl, additional, Kronbichler, Andreas, additional, Demoulin, Nathalie, additional, Bovy, Christophe, additional, Hellemans, Rachel, additional, Hougardy, Jean-Michel, additional, Sprangers, Ben, additional, Wissing, Karl Martin, additional, Pagnoux, Christian, additional, Barbour, Sean, additional, Brachemi, Soumeya, additional, Cournoyer, Serge, additional, Girard, Louis-Philippe, additional, Laurin, Louis-Philippe, additional, Liang, Patrick, additional, Philibert, David, additional, Walsh, Michael, additional, Tesar, Vladimir, additional, Becvar, Radim, additional, Horak, Pavel, additional, Rychlik, Ivan, additional, Szpirt, Wladimir, additional, Dieperink, Hans, additional, Gregersen, Jon Waarst, additional, Ivarsen, Per, additional, Krarup, Elizabeth, additional, Lyngsoe, Cecilie, additional, Rigothier, Claire, additional, Augusto, Jean-Francois, additional, Belot, Alexandre, additional, Chauveau, Dominique, additional, Cornec, Divi, additional, Jourde-Chiche, Noemie, additional, Ficheux, Maxence, additional, Karras, Alexandre, additional, Klein, Alexandre, additional, Maurier, Francois, additional, Mesbah, Rafik, additional, Moranne, Olivier, additional, Neel, Antoine, additional, Quemeneur, Thomas, additional, Saadoun, David, additional, Terrier, Benjamin, additional, Zaoui, Philippe, additional, Schaier, Matthias, additional, Benck, Urs Tobias, additional, Bergner, Raoul, additional, Busch, Martin, additional, Floege, Juergen, additional, Grundmann, Franziska, additional, Haller, Hermann, additional, Haubitz, Marion, additional, Hellmich, Bernhard, additional, Henes, Joerg Christoph, additional, Hohenstein, Bernd, additional, Hugo, Christian, additional, Iking-Konert, Christof, additional, Arndt, Fabian, additional, Kubacki, T, additional, Kotter, Ina, additional, Lamprecht, Peter, additional, Lindner, Tom, additional, Halbritter, Jan, additional, Mehling, Heidrun, additional, Schönermarck, Ulf, additional, Venhoff, Nils, additional, Vielhauer, Volker, additional, Witzke, Oliver, additional, Szombati, Istvan, additional, Szucs, Gabriella, additional, Garibotto, Giacomo, additional, Alberici, Federico, additional, Brunetta, Enrico, additional, Dagna, Lorenzo, additional, De Vita, Salvatore, additional, Emmi, Giacomo, additional, Gabrielli, Armando, additional, Manenti, Lucio, additional, Pieruzzi, Federico, additional, Roccatello, Dario, additional, Salvarani, Carlo, additional, Harigai, Masayoshi, additional, Dobashi, Hiroaki, additional, Atsumi, Tatsuya, additional, Fujimoto, Shoichi, additional, Hagino, Noboru, additional, Ihata, Atsushi, additional, Kaname, Shinya, additional, Kaneko, Yuko, additional, Katagiri, Akira, additional, Katayama, Masao, additional, Kirino, Yohei, additional, Kitagawa, Kiyoki, additional, Komatsuda, Atsushi, additional, Kono, Hajime, additional, Kurasawa, Takahiko, additional, Matsumura, Ryutaro, additional, Mimura, Toshihide, additional, Morinobu, Akio, additional, Murakawa, Yohko, additional, Naniwa, Taio, additional, Nanki, Toshihiro, additional, Ogawa, Noriyoshi, additional, Oshima, Hisaji, additional, Sada, Kenei, additional, Sugiyama, Eiji, additional, Takeuchi, Tohru, additional, Taki, Hirofumi, additional, Tamura, Naoto, additional, Tsukamoto, Tatsuo, additional, Yamagata, Kunihiro, additional, Yamamura, Masahiro, additional, van Daele, Paulus Leon Arthur, additional, Rutgers, Abraham, additional, Teng, Y.K. Onno, additional, Walker, Robert, additional, Chua, Ignatius, additional, Collins, Michael, additional, Rabindranath, Kannaiyan, additional, de Zoysa, Janak, additional, Svensson, My Hanna Sofia, additional, Grevbo, Bard-Waldum, additional, Kalstad, Synove, additional, Little, Mark, additional, Clarkson, Michael, additional, Molloy, Eamonn, additional, Agraz Pamplona, Irene, additional, Anton, Jordi, additional, Barrio Lucia, Vicente, additional, Ciggaran, Secundino, additional, Cinta Cid, Maria, additional, Diaz Encarnacion, Montserrat, additional, Fulladosa Oliveras, Xavier, additional, Jose Soler, Maria, additional, Marco Rusinol, Helena, additional, Praga, Manuel, additional, Quintana Porras, Luis, additional, Segarra, Alfons, additional, Bruchfeld, Annette, additional, Segelmark, Marten, additional, Soveri, Inga, additional, Thomaidi, Eleni, additional, Westman, Kerstin, additional, Neumann, Thomas, additional, Burnier, Michel, additional, Daikeler, Thomas, additional, Dudler, Jean, additional, Hauser, Thomas, additional, Seeger, Harald, additional, Vogt, Bruno, additional, Burton, James, additional, Al Jayyousi, Reem, additional, Amin, Tania, additional, Andrews, Jacqueline, additional, Baines, Laura Anne, additional, Brogan, Paul, additional, Dasgupta, Bhaskar, additional, Doulton, Timothy William Ronald, additional, Flossmann, Oliver, additional, Griffin, Sian V., additional, Harper, Janice Marian, additional, Harper, Lorraine, additional, Kidder, Dana, additional, Klocke, Rainer, additional, Lanyon, Peter Charles, additional, Luqmani, Raashid, additional, McLaren, John Stuart, additional, Makanjuola, David Osagie, additional, McCann, Liza, additional, Nandagudi, Anupama C., additional, Selvan, Shilpa, additional, O'Riordan, Edmond, additional, Patel, Mumtaz, additional, Patel, Rajan Kantilal, additional, Pusey, Charles Dickson, additional, Rajakariar, Ravindra, additional, Robson, Joanna C., additional, Robson, Michael, additional, Salama, Alan David, additional, Smyth, Lucy, additional, Sznajd, Jan, additional, Taylor, Joanne, additional, Sreih, Antonie G., additional, Belilos, Elise, additional, Bomback, Andrew S., additional, Carlin, Jeffrey, additional, Chang Chen Lin, Yih, additional, Derebail, Vimal K., additional, Dragoi, Serban, additional, Dua, Anisha, additional, Forbess, Lindsy, additional, Geetha, Duvuru, additional, Gipson, Patrick, additional, Gohh, Reginald, additional, Greenwood, Gregory Todd, additional, Hugenberg, Steven T., additional, Jimenez, Richard A.H., additional, Kaskas, Marwan Omar, additional, Kermani, Tanaz, additional, Kivitz, Alan J., additional, Koening, Curry, additional, Langford, Carol A., additional, Marder, Galina, additional, Mohamed, Amr Ahmed El-Huesseini, additional, Monach, Paul, additional, Neyra, Nilda Roxana, additional, Niemer, Gregory W., additional, Niles, John, additional, Obi, Reginald, additional, Owens, Charles, additional, Parks, Deborah L., additional, Podoll, Amber S., additional, Rovin, Brad, additional, Sam, R, additional, Shergy, William Julius, additional, Silva, Arnold Lawrence, additional, Specks, Ulrich, additional, Spiera, Robert, additional, Springer, Jason M., additional, Striebich, Christopher Charles, additional, Swarup, Areena, additional, Thakar, Surabhi, additional, Tiliakos, Athan N., additional, Tsai, Yong, additional, Waguespack, Dia R., additional, and Chester Wasko, Mary, additional

Published
2023
Full Text
View/download PDF

30. Hydrochlorothiazide and Prevention of Kidney-Stone Recurrence

Author

Dhayat, Nasser A, Bonny, Olivier, Roth, Beat, Christe, Andreas, Ritter, Alexander, Mohebbi, Nilufar, Faller, Nicolas, Pellegrini, Lisa, Bedino, Giulia, Venzin, Reto M, Grosse, Philipp, Hüsler, Carina, Koneth, Irene, Bucher, Christian, Del Giorno, Rosaria, Gabutti, Luca, Mayr, Michael, Odermatt, Urs, Buchkremer, Florian, Ernandez, Thomas, Stoermann-Chopard, Catherine, Teta, Daniel, Vogt, Bruno, Roumet, Marie, Tamò, Luca, Cereghetti, Grazia M, Trelle, Sven, and Fuster, Daniel G

Subjects
570 Life sciences, biology, General Medicine, 610 Medicine & health
Abstract

BACKGROUND Nephrolithiasis is one of the most common conditions affecting the kidney and is characterized by a high risk of recurrence. Thiazide diuretic agents are widely used for prevention of the recurrence of kidney stones, but data regarding the efficacy of such agents as compared with placebo are limited. Furthermore, dose-response data are also limited. METHODS In this double-blind trial, we randomly assigned patients with recurrent calcium-containing kidney stones to receive hydrochlorothiazide at a dose of 12.5 mg, 25 mg, or 50 mg once daily or placebo once daily. The main objective was to investigate the dose-response effect for the primary end point, a composite of symptomatic or radiologic recurrence of kidney stones. Radiologic recurrence was defined as the appearance of new stones on imaging or the enlargement of preexisting stones that had been observed on the baseline image. Safety was also assessed. RESULTS In all, 416 patients underwent randomization and were followed for a median of 2.9 years. A primary end-point event occurred in 60 of 102 patients (59%) in the placebo group, in 62 of 105 patients (59%) in the 12.5-mg hydrochlorothiazide group (rate ratio vs. placebo, 1.33; 95% confidence interval [CI], 0.92 to 1.93), in 61 of 108 patients (56%) in the 25-mg group (rate ratio, 1.24; 95% CI, 0.86 to 1.79), and in 49 of 101 patients (49%) in the 50-mg group (rate ratio, 0.92; 95% CI, 0.63 to 1.36). There was no relation between the hydrochlorothiazide dose and the occurrence of a primary end-point event (P = 0.66). Hypokalemia, gout, new-onset diabetes mellitus, skin allergy, and a plasma creatinine level exceeding 150% of the baseline level were more common among patients who received hydrochlorothiazide than among those who received placebo. CONCLUSIONS Among patients with recurrent kidney stones, the incidence of recurrence did not appear to differ substantially among patients receiving hydrochlorothiazide once daily at a dose of 12.5 mg, 25 mg, or 50 mg or placebo once daily. (Funded by the Swiss National Science Foundation and Inselspital; NOSTONE ClinicalTrials.gov number, NCT03057431.).

Published
2023

35. Diabetic kidney disease in type 2 diabetes: a consensus statement from the Swiss Societies of Diabetes and Nephrology

Author

Zanchi, Anne, Jehle, Andreas W, Lamine, Faiza, Vogt, Bruno, Czerlau, Cecilia, Bilz, Stefan, Seeger, Harald, de Seigneux, Sophie, Zanchi, Anne, Jehle, Andreas W, Lamine, Faiza, Vogt, Bruno, Czerlau, Cecilia, Bilz, Stefan, Seeger, Harald, and de Seigneux, Sophie

Abstract

Diabetic kidney disease is highly prevalent in patients with type 2 diabetes and is a major cause of end-stage renal disease in Switzerland. Patients with diabetic kidney disease are among the most complex patients in diabetes care. They require a multifactorial and multidisciplinary approach with the goal to slow the decline in glomerular filtration rate (GFR) and cardiovascular morbidity. With this consensus we propose an evidence-based guidance to health care providers involved in the care of type 2 diabetic patients with diabetic kidney disease.First, there is a need to increase physician awareness and improve screening for diabetic kidney disease as early intervention may improve clinical outcomes and the financial burden. Evaluation of estimated GFR (eGFR) and spot urine albumin/creatinine ratio is recommended at least annually. Once it is diagnosed, glucose control and optimisation of blood pressure control with renin-angiotensin system blockers have been recommended as mainstay management of diabetic kidney disease for more than 20 years. Recent, high quality randomised controlled trials have shown that sodium-glucose cotransporter-2 (SGLT2) inhibition slows eGFR decline and cardiovascular events beyond glucose control. Likewise, mineralocorticoid receptor antagonism with finerenone has cardiorenal protective effects in diabetic kidney disease. Glucagon-like peptide-1 (GLP1) receptor agonists improve weight loss if needed, and decrease albuminuria and cardiovascular morbidity. Lipid control is also important to decrease cardiovascular events. All these therapies are included in the treatment algorithms proposed in this consensus. With advancing kidney failure, other challenges may rise, such as hyperkalaemia, anaemia and metabolic acidosis, as well as chronic kidney disease-mineral and bone disorder. These different topics and treatment strategies are discussed in this consensus. Finally, an update on diabetes management in renal replacement therapy such as

Published
2023

36. The genetic architecture of membranous nephropathy and its potential to improve non-invasive diagnosis

Author

Xie, Jingyuan, Liu, Lili, Mladkova, Nikol, Li, Yifu, Ren, Hong, Wang, Weiming, Cui, Zhao, Lin, Li, Hu, Xiaofan, Yu, Xialian, Xu, Jing, Liu, Gang, Caliskan, Yasar, Sidore, Carlo, Balderes, Olivia, Rosen, Raphael J., Bodria, Monica, Zanoni, Francesca, Zhang, Jun Y., Krithivasan, Priya, Mehl, Karla, Marasa, Maddalena, Khan, Atlas, Ozay, Fatih, Canetta, Pietro A., Bomback, Andrew S., Appel, Gerald B., Sanna-Cherchi, Simone, Sampson, Matthew G., Mariani, Laura H., Perkowska-Ptasinska, Agnieszka, Durlik, Magdalena, Mucha, Krzysztof, Moszczuk, Barbara, Foroncewicz, Bartosz, Pączek, Leszek, Habura, Ireneusz, Ars, Elisabet, Ballarin, Jose, Mani, Laila-Yasmin, Vogt, Bruno, Ozturk, Savas, Yildiz, Abdülmecit, Seyahi, Nurhan, Arikan, Hakki, Koc, Mehmet, Basturk, Taner, Karahan, Gonca, Akgul, Sebahat Usta, Sever, Mehmet Sukru, Zhang, Dan, Santoro, Domenico, Bonomini, Mario, Londrino, Francesco, Gesualdo, Loreto, Reiterova, Jana, Tesar, Vladimir, Izzi, Claudia, Savoldi, Silvana, Spotti, Donatella, Marcantoni, Carmelita, Messa, Piergiorgio, Galliani, Marco, Roccatello, Dario, Granata, Simona, Zaza, Gianluigi, Lugani, Francesca, Ghiggeri, GianMarco, Pisani, Isabella, Allegri, Landino, Sprangers, Ben, Park, Jin-Ho, Cho, BeLong, Kim, Yon Su, Kim, Dong Ki, Suzuki, Hitoshi, Amoroso, Antonio, Cattran, Daniel C., Fervenza, Fernando C., Pani, Antonello, Hamilton, Patrick, Harris, Shelly, Gupta, Sanjana, Cheshire, Chris, Dufek, Stephanie, Issler, Naomi, Pepper, Ruth J., Connolly, John, Powis, Stephen, Bockenhauer, Detlef, Stanescu, Horia C., Ashman, Neil, Loos, Ruth J. F., Kenny, Eimear E., Wuttke, Matthias, Eckardt, Kai-Uwe, Köttgen, Anna, Hofstra, Julia M., Coenen, Marieke J. H., Kiemeney, Lambertus A., Akilesh, Shreeram, Kretzler, Matthias, Beck, Lawrence H., Stengel, Benedicte, Debiec, Hanna, Ronco, Pierre, Wetzels, Jack F. M., Zoledziewska, Magdalena, Cucca, Francesco, Ionita-Laza, Iuliana, Lee, Hajeong, Hoxha, Elion, Stahl, Rolf A. K., Brenchley, Paul, Scolari, Francesco, Zhao, Ming-hui, Gharavi, Ali G., Kleta, Robert, Chen, Nan, and Kiryluk, Krzysztof

Published
2020
Full Text
View/download PDF

40. Applications of the Microscale Thermophoresis Binding Assay in COVID-19 Research

Author

Nydegger, Damian T., Pujol-Giménez, Jonai, Kandasamy, Palanivel, Vogt, Bruno, and Hediger, Matthias A.

Subjects
570 Life sciences, biology, 610 Medicine & health
Abstract

As the COVID-19 pandemic progresses, new variants of SARS-CoV-2 continue to emerge. This underscores the need to develop optimized tools to study such variants, along with new coronaviruses that may arise in the future. Such tools will also be instrumental in the development of new antiviral drugs. Here, we introduce microscale thermophoresis (MST) as a reliable and versatile tool for coronavirus research, which we demonstrate through three different applications described in this report: (1) binding of the SARS-CoV-2 spike receptor binding domain (RBD) to peptides as a strategy to prevent virus entry, (2) binding of the RBD to the viral receptor ACE2, and (3) binding of the RBD to ACE2 in complex with the amino acid transporter SLC6A20/SIT1 or its allelic variant rs61731475 (p.Ile529Val). Our results demonstrate that MST is a highly precise approach to studying protein–protein and/or protein–ligand interactions in coronavirus research, making it an ideal tool for studying viral variants and developing antiviral agents. Moreover, as shown in our results, a unique advantage of the MST assay over other available binding assays is the ability to measure interactions with membrane proteins in their near-native plasma membrane environment.

Published
2023
Full Text
View/download PDF

41. The Urine-to-Plasma Urea Concentration Ratio is associated with eGFR and eGFR decline over time in a population cohort

Author

Petrovic, Dusan, Bankir, Lise, Ponte, Belén, Pruijm, Menno, Corre, Tanguy, Ghobril, Jean-Pierre, Bouatou, Yassine, Ackermann, Daniel, Vogt, Bruno, and Bochud, Murielle

Subjects
610 Medicine & health
Abstract

BACKGROUND Evaluation of renal function and of factors associated with its decline are important public health issues. Besides markers of glomerular function (e.g., GFR), those of tubular functions are rarely evaluated. Urea, the most abundant urinary solute, is markedly concentrated in urine when compared to plasma. We explored the urine-to-plasma ratio of urea concentrateions (U/P-urea-ratio) as a marker of tubular functions. METHODS We evaluated the relationship of the U/P-urea-ratio with eGFR at baseline in 1043 participants (48±17y) from the SKIPOGH population-based cohort, using mixed regression. In 898 participants, we assessed the relation between U/P-urea-ratio and renal function decline between two study waves 3 years apart. We studied U/P ratios for osmolarity, Na, K, uric acid for comparison. RESULTS In a transversal study at baseline, eGFR was positively associated with U/P-urea-ratio (βscaled = 0.08, 95%CI[0.04;0.13]) but not with the U/P ratio of osmolarity. Considering separately participants with renal function > or ≤ 90 ml/minx1.73m2, this association was observed only in those with reduced renal function. In the longitudinal study, eGFR declined at a mean rate of 1.2 ml/min per year. A significant association was observed between baseline U/P-urea-ratio and eGFR decline (βscaled = 0.08, 95%CI[0.01;0.15]). A lower baseline U/P-urea-ratio was associated with a greater eGFR decline. CONCLUSION This study provides evidence that the U/P-urea-ratio is an early marker of kidney function decline in the general adult population. Urea is easy to measure with well-standardized techniques and at low cost. Thus, the U/P-urea-ratio could become an easily available tubular marker for evaluating renal function decline.

Published
2023
Full Text
View/download PDF

42. Tolvaptan treatment is associated with altered mineral metabolism parameters and increased bone mineral density in ADPKD patients.

Author

Bargagli, Matteo, Vetsch, Andri, Anderegg, Manuel A, Dhayat, Nasser A, Huynh-Do, Uyen, Faller, Nicolas, Vogt, Bruno, Ferraro, Pietro Manuel, and Fuster, Daniel G

Subjects
BONE density, POLYCYSTIC kidney disease, BICARBONATE ions, DUAL-energy X-ray absorptiometry, MINERAL supplements
Abstract

Background Autosomal dominant polycystic kidney disease (ADPKD) is characterized by a unique bone and mineral phenotype. The impact of tolvaptan treatment on mineral metabolism and bone mineral density (BMD) is unknown. Methods We conducted an analysis in the Bern ADPKD Registry, a prospective observational cohort study. Mineral metabolism parameters were measured at baseline and every 12 months thereafter. BMD was determined by dual-energy X-ray absorptiometry at baseline and after 3 years. Multivariable mixed-effects regression models were applied to assess changes in mineral metabolism parameters and BMD associated with tolvaptan treatment. Results A total of 189 participants (122 without and 67 with subsequent tolvaptan treatment) were included in the analysis. During follow-up, tolvaptan treatment was associated with increased BMD at the femoral neck {β = 0.092 [95% confidence interval (CI) 0.001–0.183], P  = .047}. In addition, tolvaptan treatment was associated with higher plasma magnesium [β = 0.019 (95% CI 0.001–0.037), P  = .037], bicarbonate [β = 0.972 (95% CI 0.242–1.702), P  = .009] and urine pH [β = 0.214 (95% CI 0.056–0.372), P  = .008] and lower parathyroid hormone [β = −0.191 (95% CI −0.328 to −0.053), P  = .006], 1,25(OH)D3 [β = −0.126 (95% CI −0.235 to −0.164), P  = .024] and fractional urinary magnesium excretion [β = −0.473 (95% CI −0.622 to −0.324), P  < .001]. Conclusions Chronic tolvaptan treatment is associated with increased femoral BMD and significant changes in both mineral metabolism and acid–base parameters in ADPKD patients. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

43. Efficacy of standard and low dose hydrochlorothiazide in the recurrence prevention of calcium nephrolithiasis (NOSTONE trial): protocol for a randomized double-blind placebo-controlled trial

Author

Dhayat, Nasser A., Faller, Nicolas, Bonny, Olivier, Mohebbi, Nilufar, Ritter, Alexander, Pellegrini, Lisa, Bedino, Giulia, Schönholzer, Carlo, Venzin, Reto M., Hüsler, Carina, Koneth, Irene, Del Giorno, Rosaria, Gabutti, Luca, Amico, Patrizia, Mayr, Michael, Odermatt, Urs, Buchkremer, Florian, Ernandez, Thomas, Stoermann-Chopard, Catherine, Teta, Daniel, Rintelen, Felix, Roumet, Marie, Irincheeva, Irina, Trelle, Sven, Tamò, Luca, Roth, Beat, Vogt, Bruno, and Fuster, Daniel G.

Published
2018
Full Text
View/download PDF

45. PhenoExplorer: An Interactive Web-based Platform for Exploring (Epi)Genome-Wide Associations Using a Swiss Population-based Study

Author

Ghobril, Jean-Pierre, primary, Petrovic, Dusan, additional, Ehret, Georg, additional, Ponte, Belén, additional, Pruijm, Menno, additional, Ackermann, Daniel, additional, Vogt, Bruno, additional, Stringhini, Silvia, additional, Thomas, Aurélien, additional, Chamberlain, Jonviea, additional, Gonseth-Nusslé, Semira, additional, and Bochud, Murielle, additional

Published
2022
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results